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PREFACE
My passion for public health developed first from a desire to understand more about
the context of medicine – we do not practice medicine in a vacuum, and so to consider
medicine only from a physiological point of view is absurd. By taking interest in the
denominator as well as the numerator, by looking at whole communities, large environments,
umbrella policies, and socioeconomic barriers to healthcare, physicians can provide better
quality care for their patients by meeting patient needs instead of physicians’ or
administrators’ needs. Medicine and the need for patient advocates within medicine becomes
powerfully relevant when viewed through the lens of public health. This project, specifically,
grew out of an evident need for patients to have higher quality follow-up referral after
discharge from the Emergency Department (ED), to receive a “warm handoff” in the words
of one my mentors, instead of a cold or absent one. My hope is that this work can be used to
improve the quality of patient referrals made in the ED.
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ABSTRACT
Background: One strategy to decrease uncontrolled hypertension is to increase
follow-up with primary care after diagnosis of asymptomatic hypertension in the Emergency
Department (ED). To improve such interventions, this study identified risk factors of nonadherence among individuals 18-60 years old with a diagnosis of asymptomatic hypertension
in the ED and access to care.
Methods: Data was obtained from the IBM® MarketScan® Commercial Database
between January 2012 and September 2015. Rates of non-adherence to follow-up was
determined for individuals discharged from the ED with a primary diagnosis of essential
hypertension. Multivariate logistic regression was used to calculate adjusted odds ratios.
Demographic and structural variables were evaluated to determine their relationship with
non-adherence to follow-up.
Results: Two-thirds of the study population did not adhere to follow-up within 30
days. Risk factors for non-adherence included no history of recent visit with primary care
(OR=1.87; 95% CI=1.81-1.93) and multiple prior ED visits (OR=1.65; 95% CI=1.57-1.73).

Protective characteristics included history of filling an anti-hypertensive prescription in last
year (OR=0.42; 95% CI=0.40-0.43); or history of filling a 30-day anti-hypertensive
prescription on day of index event (OR=0.83; 95% CI=0.80-0.87).
Conclusion: Individuals who have not visited primary care or who are at the ED for
the third time in 12 months are more likely to be non-adherent to follow-up. History of filling
a 30-day anti-hypertensive prescription within one day of index event or in prior 12 months
is associated with increased adherence to follow-up and should be further explored as a
strategy for encouraging follow-up in this population.
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BACKGROUND
Literature Review
Hypertension in the ED. Hypertension and hypertension-related complaints in the ED are not
only prevalent but have increased over the last decade in both the United States and
Canada1,2. Individuals who present in the ED with hypertension, defined for individuals
under 60 years of age by the Eighth Report of the Joint National Committee (JNC 8) to be
blood pressure greater than or equal to 140 mm Hg systolic or greater than or equal to 90 mm
Hg diastolic3, can be loosely categorized into three groups: those who have incidental high
blood pressure findings unrelated to the chief complaint and are left undiagnosed, those who
have high blood pressure diagnosed in the ED but do not exhibit acute symptoms of
hypertension-related end-organ damage and are subsequently discharged for follow-up with
primary care, and those with a chief complaint that may or may not be hypertension but who
are experiencing acute hypertension-related end-organ damage.

The first of these groups, and perhaps the largest proportion of individuals, are left
undiagnosed and therefore cannot be studied with a claims dataset4,5. The last of these
groups, clearly not asymptomatic, requires emergent admittance to the hospital for treatment.
However, the second group represents individuals at risk for falling into the population of
hypertensive adults described previously, who have uncontrolled hypertension, a diagnosis,
and, if they have insurance, access to care. Interestingly, despite decreases in hospitalization
of hypertensive patients in the ED from 2006 to 2012, ED visits with a primary diagnosis of
hypertension increased 4.4% each year and comprised about 1% of all adult ED visits2. It can
1

be inferred, then, that relatively more individuals are falling into this second group of
individuals who are diagnosed with asymptomatic hypertension and discharged from the ED.
This group of individuals is the subject of interest for this study.

Hypertensive individuals without acute end-organ damage discharged from the ED with or
without treatment or a prescription for antihypertensive medication have an overall low-risk
of short-term risk of complications1,6,7. Guidelines suggest the discharging physician can
decide whether to prescribe antihypertensive medication, to refer to a Primary Care Physician
(PCP), or to do both. Recent literature goes further to suggest that emergency physicians do
have a role in screening for hypertension, in actively encouraging follow-up after an ED visit
by securing a follow-up appointment or contacting patients’ PCPs, and in using clinical
judgment to determine when prescribing antihypertensive medication is appropriate8-11.

Adherence to follow-up after ED diagnosis. Hypertension remains untreated if an individual
is referred to primary care and cannot attain follow-up, and the inaccessibility of primary
care has been proposed as an important factor in increased ED use12. Additionally, studies on
timely follow-up after referral from the ED have found that follow-up within a week is
difficult to achieve, perhaps even for those with private insurance13,14. Barriers to timely
follow-up may include race, socioeconomic status, age, history of mental illness, living
environment, insurance status, PCP status, and access to the healthcare system11. In this
study, all individuals have presumed access to the healthcare system through commercial
insurance.
2

The dependent variable examined in this study is adherence to follow-up with a PCP after
ED discharge. Interventions to increase successful follow-up after referral from the ED have
been attempted, with varying levels of success. However, it remains unclear whether one or
another method is better for increasing care coordination across more than one ED15. A better
understanding of the risk factors of non-adherence to follow-up after referral from the ED
may help to improve intervention efforts in the future and improve hypertension control
among the insured, nonelderly population.

Variables of nonadherence in the literature. Prescription nonadherence has been associated
with use of the ED for hypertensive management in minority populations16, but the
relationship between prescription nonadherence and using the ED for hypertensive
management or prescription nonadherence and nonadherence to follow-up has not been
described for a national, commercially insured population. In an attempt to understand this
relationship, this study measures prescription adherence for individuals who have a history of
hypertension prescription fills in the 12 months prior to the initial ED visit.

Other demographic variables may also have a role in nonadherence to follow-up. Age,
specifically, may play a role in hypertension control as adults aged 18-39 have lower rates of
awareness, treatment, and control compared with older adults17. Barriers related to race,
history of mental illness, or the living environment are not supported by this database.

3

Public Health Significance
Cardiovascular disease kills more people worldwide than any other cause of death, making
the risk factors for cardiovascular disease, including uncontrolled hypertension, a high
priority for interventional public health and preventive medicine18 . The prevalence of
hypertension in the United States, as mentioned previously, is significant. According to the
National Health and Nutrition Examination Survey for the years 2005-2008, 68 million
adults aged 18 years or older had hypertension. Over 50% of hypertensive adults had
uncontrolled hypertension, and of these, over 80% were aware of their diagnosis19.
Hypertension is associated with overall shorter life expectancy, and from 2000 to 2010 the
death rate attributable to high blood pressure increased by 16%20. In addition to the negative
consequences of increased blood pressure on cardiovascular health, hypertension in the U.S.
is also a source of health disparity. Of great concern are the disparities in prevalence and/or
control among non- Hispanic blacks, women, and Mexican-Americans21-24.

The monetary cost of hypertension is also significant. The 2010 estimated direct and indirect
cost of hypertension was $46.4 billion, and the direct and indirect cost of cardiovascular
disease and stroke is estimated to be $315.4 billion20. Because chronic disease management
with continuity of care is associated with fewer ED visits and lower costs25, hypertension
management at the level of the PCP is important. Similarly, because emergency care for
nonurgent conditions costs more than care in other settings26, asymptomatic hypertension is
more cost-efficiently treated in primary care settings. The increasing number of emergency
4

department visits and subsequent overcrowding of the ED is another incentive for keeping
patients out of the ED and in a primary care setting27,28.

With a greater emphasis being placed on primary care prevention to decrease healthcare costs
associated with preventable adverse events, the connection between emergency management
of asymptomatic hypertension and primary care follow-up needs to be better understood.
Risk factors identified in this study will allow for more targeted interventions in the insured,
nonelderly population to increase follow-up and, presumably, to increase likelihood of
hypertension control for those who have uncontrolled hypertension due to lack of proper
care. The association between ED visits for asymptomatic hypertension and follow-up
appointments with a PCP has not been studied. Additionally, adherence rates for follow-up
visits after any ED diagnosis for both nonelderly and commercially insured populations is
underrepresented in the literature.

Specific Aims
The first aim of this project is to determine the rate of follow-up with primary care after a
diagnosis of asymptomatic hypertension in the ED for those with commercial insurance.
Follow-up is expected to be less than 100%. The second aim of this project is to explore
predictors of non-adherence to follow-up by analyzing the relationship between nonadherence and several demographic and structural variables with multivariate logistic
regression.

5

JOURNAL ARTICLE
Title: Non-adherence to follow-up after asymptomatic hypertension in the Emergency
Department
Proposed Journal: American Journal of Emergency Medicine

I. Introduction
Hypertension (HTN) is one of the leading risk factors affecting global burden of disease and
mortality29,30. Despite recent improvements in treatment and control, over 50% of
hypertensive adults still suffer from uncontrolled HTN. Of those with uncontrolled HTN,
over 50% are aware of their diagnosis, and 85% have health insurance31. Novel strategies are
needed to improve HTN control32. Recently, Emergency Department (ED) visits with a
primary diagnosis of HTN, both with and without hospitalization, have increased,
highlighting the ED as an appropriate setting for pursuit of better HTN education, referral to
primary care, and improved adherence to follow-up1,2,33,34. A recent study found emergency
physicians are unable to predict which patients are at higher risk of non-adherence to followup with primary care35, and it remains unclear which interventions increase follow-up after
referrals15. Furthermore, adherence to follow-up after ED discharge has not been studied in
association with anti-hypertensive prescription history.

A better understanding of the risk factors for non-adherence may improve interventions in
the future and ultimately aid in reducing uncontrolled HTN for those with a known diagnosis
6

and access to care. This retrospective cohort study sought to identify demographic and
structural predictors of non-adherence to follow-up with primary care after primary diagnosis
of asymptomatic Essential HTN in the ED. Non-elderly adults, in particular, were studied
because increased control of hypertension in a non-elderly population would lead to
increased long-term morbidity and mortality benefits compared to older cohorts.

II. Methods
Data source. The study population was derived from the IBM MarketScan® Commercial
Database1, a national convenience sample of commercially insured individuals, representing
data from large employers, as well as medium and small firms36. The database includes
claims submitted by any provider who saw a covered individual, including in-network
providers, out-of-network providers, and visits denied for payment. Use of this database has
precedent in the literature and is fully compliant with the Healthcare Information Portability
and Accountability Act (HIPAA)37. The study was reviewed by the UT Houston Health
Science Center Review Board and deemed to be exempt.

Study population. This was a retrospective cohort study of commercially insured non-elderly
adults identified within the MarketScan database from 1 January 2012 through 30 September
2015. Diagnosis was based on International Classification of Diseases (ICD) -Revision 9
codes for Essential (Primary) HTN (401.1 and 401.9). Individuals included in the study were
aged 18-60 years at time of index event, were discharged from the ED without same-day

1

MarketScan is a registered trademark of IBM Corporation in the United States, other countries or both.
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admission to the hospital, were not admitted to an inpatient setting within seven days of
index event and were enrolled with insurance for at least two continuous months during the
year of the index event (see Figure 1). Inclusion criteria also required having prescription
benefit information available through the database. Total data analyzed spanned 12 months
before each index event through follow-up, defined as up to 30 days after index event.

Study definitions. Index event was defined as the first ED visit billed with a primary
diagnosis of essential hypertension (ICD 9 codes 401.1 and 401.9) without same-day
admission. The primary outcome, non-adherence to follow-up with primary care, was defined
as absence of a visit with family medicine, internal medicine, cardiology, geriatrics, nurse
practitioners (NP) or physician’s assistants (PA) within 30 days of index event. Of note, the
database does not include specialty information for NPs or PAs, but it was assumed that a
visit for primary diagnosis HTN with a NP or a PA would have occurred in one of the
previously defined primary care settings. This is referred to as the “combined analysis.” In
this analysis, individuals with a primary care visit were excluded if the billing was based on a
non-HTN primary diagnosis. While the primary diagnosis for a follow-up of uncontrolled
blood pressure would ideally be “HTN,” individuals with multiple comorbidities may have
been billed for another diagnosis, which took priority for the follow-up visit. Any contact
with primary care after discharge from the ED is clinically relevant because checking blood
pressure is standard of care for most visits, and hypertensive blood pressure findings would
likely be addressed during the encounter. Although if the primary diagnosis was not HTN, it
is unclear whether or not the blood pressure or recent ED visit was addressed at the follow-up
8

visit, these visits are relevant as a sensitivity analysis. Individuals in the sensitivity analysis
included all primary care visits within 30 days of the index event, regardless of diagnosis.
Both the primary and sensitivity analyses are included in this report.

Thirty days was chosen to represent adherence given existing literature which suggests
obtaining follow-up within one week might be an unreasonable expectation for obtaining
primary care follow-up after an ED visit in the United States, even for those with commercial
insurance13,14.

Demographics and characteristics. Explanatory variables included age and sex (with male as
reference), employment status of policy holder, dichotomized into full-time employment or
“other”; continuous insurance coverage, defined as coverage for continuous 12 months
during year of index event, or non-continuous; and type of insurance benefit plan,
dichotomized into PPO or “other.”

Structural variables were included to explore the effects of an individual’s interaction with
the medical system prior to and on the day of index event. First, the variable “Not
Established with Primary Care” was determined by selecting individuals who were not billed
for any visit during the 12 months prior to the index event with a primary care. Second,
individuals were identified as “ED High Utilizer” if they had two or more visits to the ED for
any diagnosis in the 12 months prior to index event, plus the index event, for a total of three
visits within 12 months. Third, the variable “Inpatient Admission in Prior 90 Days” was
9

determined by selecting individuals who had at least one inpatient admission in the 90 days
prior to the index event.

Finally, two pharmaceutical variables were identified. The first variable, ED Prescription,
identified individuals who filled a 30-day prescription of an anti-hypertensive medication on
the day of index event (day 0) or next day (day 1), likely indicative of prescription by an ED
physician, NPs, or PAs. When prescription fill date occurred on Day 1 and follow-up visit
also occurred on Day 1, then the individual was excluded from the model to avoid
confounding results due to PCP prescription of anti-hypertensives. Prescriptions filled after
Day 1 could not reasonably be assumed to have been written in the ED, and prescriptions for
days-supply other than 30 days were not included because these time frames did not fit the
research question. The second pharmaceutical variable described individuals who filled an
anti-hypertensive medication in the 12 months prior to index event. Anti-hypertensives
included ACE inhibitors, alpha-beta blockers, beta blockers, calcium channel blockers, loop
diuretics, potassium-sparing diuretics, thiazides, and vasodilating agents. Angiotensinreceptor blockers were not included in the analysis due to limitations of the Marketscan
database. Prescription data from this database includes mail order prescriptions and specialty
pharmacies36.

Statistical analysis. Unadjusted differences between adherent and non-adherent groups were
determined by t-tests for the continuous variable and by chi square tests for categorical
variables. Logistic regression was used to evaluate the impact of the explanatory variables on
10

non-adherence to follow-up, adjusting for all risk factors. Random split-sample crossvalidation was used to assess the validity of the model in the primary analysis. Akaike and
Bayesian information criterion, as well as area under the receiver operator curve, were used
to compare relative fit between the model developed in the training sample and the model fit
by the validation sample. For sensitivity analysis, we examined differences between the odds
ratios for our combined analysis and for those from the sensitivity analysis (any primary
diagnosis). Stata 15.1 (StataCorp LLC, College Station, Texas) was used to conduct all
analyses38.

III. Results
Characteristics of study subjects: A total of 84,929 individuals met inclusion criteria for this
study. The study population included individuals aged 18-60 years, with a mean age of 47.3
(SD = 9.7). A total of 57% were female, and age distribution between males and females was
consistent. Plan and coverage information can be found in Table 1. For those who adhered to
follow-up, primary care visits were completed with family practice (53%), internal medicine
(33%), cardiology (10%), geriatrics (1%), or with a nurse practitioner or physician’s assistant
(3%). Table 1 describes the characteristics of the combined analysis. There was no missing
data in the dataset. Graph 2 shows the day of first follow-up visit for primary diagnosis HTN.
Follow-up rate was much decreased after seven days.

Main results: Overall, this study found 66% non-adherence to follow-up for HTN after
discharge from the ED. A total of 30,448 (35.9%) individuals had no history of a PCP visit in
11

the 12 months prior to their index event. Only 4.9% of individuals had a recent inpatient
admission, and 11.7% visited the ED two or more times in the 12 months prior to index
event. A majority (76.1%) of individuals filled a prescription for anti-hypertensive
medication in the 12 months prior to index event, and 13.9% filled a 30-day prescription for
anti-hypertensive medication on the day of index event (Day 0) or next-day (Day 1). Of note,
86.2% of those who filled a 30-day prescription for anti-hypertensives also had a history of
filling an antihypertensive prescription in the last 12 months, and 30-day prescriptions
represent 77% of all prescriptions filled on day 0 to 1 (see Appendix B).

Table 2 shows the adjusted odds ratio for each characteristic in its relationship to nonadherence in the combined model and cross validation models (i.e., training sample and
validation sample). Sex and age were not significantly associated with non-adherence.
Continuous coverage and PPO-type insurance were statistically significant. Other significant
risk factors for non-adherence to follow-up included no history of PCP visit in the prior 12
months (adj. OR=1.81; 95% CI=1.76-1.86), being a high-utilizer of the ED (adj. OR=1.63;
95% CI=1.56-1.71), and history of inpatient admission in the prior three months (adj.
OR=1.36; 95% CI=1.28-1.46). Protective characteristics included history of filling a 30-day
prescription for anti-hypertensives on Day 0-1 (adj. OR=0.81; 95% CI=0.78-0.84), history of
filling anti-hypertensive prescriptions in the past year (adj. OR=0.42; 95% CI=0.41-0.44),
continuous coverage (adj. OR=0.94; 95% CI=0.90-0.98) and PPO-type insurance (adj.
OR=0.91; 95% CI=0.88-0.94]. Cross validation models included similar findings, with the
exception of a non-significant finding for continuous coverage in the validation sample.
12

Akaike and Bayesian information criterion are included in Table 2, and area under the
receiver operator curve (ROC) showed modest fit for each analysis. The sensitivity model,
which included individuals with PCP follow-up for any diagnosis within 30 days, also had
similar findings except that inpatient admission was non-significant and the variable “Not
established with PCP” was much more significantly associated with non-adherence compared
to the combined analysis (3.07 compared to 1.87). The rest of the results of the sensitivity
analysis can be found in Appendix A and are discussed in section IV.

IV. Discussion
In this study, 66% of the population did not adhere to follow-up within 30 days of an ED
visit for hypertension. Predictors for nonadherence included no history of PCP visit in the
prior 12 months, at least three visits to the ED within 12 months, and recent inpatient visit in
the prior 3 months. Factors associated with adherence included filling a 30-day
antihypertensive on day 0-1 after index event, history of filled antihypertensive in the last 12
months, PPO-type insurance, and full-time employment.

While other studies have shown that patient-reported lack of a PCP is associated with nonadherence to ED follow-up appointments, this study looked specifically at patient history to
show the negative association between lack of recent contact with a PCP and nonadherence
to follow-up39,40. It is likely that lack of a PCP and/or lack of a recent PCP visit are both
contributing factors to this finding, and future interventions should include both those
13

without a reported PCP and those who have not been in contact with a PCP in the last 12
months.

Previous research has also found that follow-up within seven days is difficult to obtain and
recent hypertension guidelines suggest that severe asymptomatic hypertension can be
followed up within 2-4 weeks from an initial encounter12,14,41; however, the rate of office
visits seen in this study was much decreased after seven days, and the overall rate is
consistent with rates in prior studies with shorter follow-up periods, indicating that extension
of the follow-up surveillance window to 30 days after the ED visit does not result in
increased adherence to follow-up13. It appears that the barriers to follow-up are not exclusive
to short-term (within 7 days) follow-up but apply to long-term (within 30 days) follow-up as
well. The rate of nonadherence in this study is also consistent with prior evidence that even
those with commercial insurance encounter barriers to adhering to follow-up13. Interventions
to increase adherence to follow-up should continue to focus on individuals both with and
without insurance.

Filling a 30-day anti-hypertensive prescription within one day of the index event was
significantly associated with adherence to follow-up. Because the majority (86%) of those
who filled this prescription had a history of filling anti-hypertensives, it is possible that these
individuals were filling a prescription that was already on file at the pharmacy instead of a
prescription from the ED. Regardless of whether the ED physician or a PCP prescribed the
anti-hypertensive, it appears that for the 14% of the population who filled a prescription for
14

anti-hypertensives within one day of index event, adherence was more likely. Adherence was
also more likely for those who filled an anti-hypertensive in the 12 months prior to the index
event, which could be indicative of increased adherence due to familiarity with the disease or
due to familiarity with a PCP. ED physicians should be encouraged that prescription of antihypertensives increases likelihood of follow-up. This intervention may be especially useful
when applied to those who have history of taking anti-hypertensives because, notably,
although 76% of the population filled a prescription for anti-hypertensives in the prior 12
months, only 14% of the population filled a prescription on day 0 or day 1 after the index
event. This represents a large potential population for intervention.

Those with three or more visits to the ED in 12 months were found to be significantly at risk
for non-adherence to follow-up. While this represented a minority (12%) of the study
population, ED physicians should recognize individuals on their third visit to the ED within
12 months to be at high risk of not adhering to follow-up for a diagnosis of uncontrolled
HTN, and these individuals may require greater interventional efforts.

Recent inpatient admission was found to be a significant risk factor in the primary model but
non-significant in the sensitivity model. This likely reflects individuals who followed up but
had a comorbid condition that took priority over HTN in the primary diagnosis for billing.
Recent inpatient admission does not appear to be a clinically significant risk factor for nonadherence to follow-up. The other difference found between the combined and sensitivity
analyses was that not seeing a PCP in the last 12 months was more significantly associated
15

with non-adherence. Like the previous difference, this is likely because the group of
individuals with multiple comorbidities (and therefore higher likelihood of having visited
their PCP in the prior 12 months) are included in the broadened primary outcome, and those
that are left in the non-adherent group are more likely to be those who do not have multiple
comorbidities and have not seen a PCP for any reason.

The association between having PPO-type insurance or Full-time employment and adherence
to follow-up is a novel finding in the ED follow-up literature. These could be important clues
to the ED physicians on which individuals should be targeted for intervention. This study
found no significant difference in follow-up rates based on sex, although females are known
to be disproportionately affected by HTN and have not experienced the same improvements
in HTN control over the last thirty years21.

V. Limitations
This study has several limitations. First, primary diagnosis of HTN was based on ICD-9
codes in claims data, allowing the possibility of misclassification of diagnoses. This is a wellknown limitation to large claims database studies. Second, this is a descriptive study and
does not represent causal evidence. Individuals adherent to follow-up may differ from those
who are non-adherent in other ways not measured by this study. Specifically, due to
limitations of the database, this study lacks individual demographic and socioeconomic
variables that may contribute to non-adherence to follow-up, such as race, socioeconomic
status, the living environment, and history of mental illness, and these should be examined in
16

future research11. Additionally, this database is reported to disproportionately represent the
southern regions of the United States compared to other regions, which must be taken into
account when interpreting the results42. Another database limitation is exclusion of visits or
services rendered for cash in which no claim was submitted to the insurance company.
Regarding prescription limitations, Angiotensin-Receptor Blockers (ARBs) are not included
as a cardiac medication subgroup in the Marketscan Database and therefore cannot be
identified separate from other cardiac medications. The authors of this study presume that
individuals taking ARBs would have similar behavior to those taking other antihypertensives included in the study. Finally, this is a national convenience sample
representative of the non-elderly, commercially insured population, and results should not be
generalized to the uninsured or elderly populations. More research should be conducted to
see if these predictors also exist in other populations.

VI. Conclusion
The results of this study have several implications for emergency medicine and primary care
interventions. First, the association between lack of history of PCP visit and non-adherence
to follow-up may indicate that obtaining a “new-patient” visit or that obtaining a PCP visit
after significant time without PCP contact is a limiting factor. Second, this study found
several populations to target in future ED interventions to increase hypertension control,
including individuals without history of a PCP visit or history of filling an anti-hypertensive
prescription in the last year and individuals who visited the ED at least three times within 12
months. ED physicians should also be encouraged to prescribe 30-day anti-hypertensives to
17

those with asymptomatic hypertension in the ED, especially to those who have taken antihypertensives in the past, because it is associated with increased rates of follow-up with
primary care.
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Table 1: Characteristics of population
Primary Analysis
Total (% total)

Characteristic

Non-Adherent (%Row) Adherent (%Row)

n= 84,929

n= 56,210 (66.2%)

n= 28,719 (33.8%)

47.3; 9.7

46.9: 9.9

48.1; 9.4

Female

47,970 (56.5%)

31,569 (65.8%)

16,401 (34.2%)

Full Time Employment

49,244 (58.0%)

31,780 (64.5%)

17,464 (35.5%)

PPO Insurance

54,105 (63.7%)

35,459 (65.5%)

18,646 (34.5%)

72,347 (85.2%)

47,278 (65.4%)

25,069 (34.7%)

30,448 (35.9%)

22,829 (75.0%)

7,619 (25.0%)

9,940 (11.7%)

7,367 (74.1%)

2,573 (25.9%)

4,134 (4.9%)

2,960 (71.6%)

1,174 (28.4%)

11,769 (13.9%)

7,278 (61.8%)

4,491 (38.2%)

64,632 (76.1%)

39,878 (61.7%)

24,754 (38.3%)

Age, mean; standard deviation

Continuous Coverage

1

Not Established with Primary Care
ED High Utilizer

2

3

Inpatient Admission in prior 90 days
Filled 30-Day Anti-HTN Rx from ED

4

Filled Anti-HTN Rx in prior 12 months

Enrolled for 12 months during year of index event
No history of primary care visit in past 12 months, any diagnosis
History of ≥2 prior ED visits in 12 months prior to ED visit, any diagnosis
Filled on day 0 or day 1 after index event

1

2

3

4
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Table 2. Adjusted odds ratios of non-adherence for combined analysis and cross validation
(training sample and validation sample)
Combined Analysis

Training Sample

Validation Sample

Adjusted OR [95% CI]

Adjusted OR [95% CI]

Adjusted OR [95% CI]

Age

0.99 [0.99-1.00]

1.00 [0.99-1.04]

0.99 [0.99-1.00]

Female

0.99 [0.96-1.02]

1.00 [0.96-1.00]

0.99 [0.95-1.03]

Full time employment

0.89 [0.86-0.92]

0.87 [0.84-0.91]

0.91 [0.86-0.95]

PPO Insurance

0.91 [0.88-0.94]

0.90 [0.86-0.94]

0.92 [0.88-0.96]

0.94 [0.90-0.98]

0.89 [0.84-0.95]

0.98 [0.92-1.04]

1.87 [1.81-1.93]

1.85 [1.77-1.94]

1.88 [1.80-1.97]

1.65 [1.57-1.73]

1.64 [1.53-1.76]

1.66 [1.55-1.78]

1.36 [1.26-1.46]

1.44 [1.30-1.59]

1.28 [1.16-1.41]

0.83 [0.80-0.87]

0.81 [0.76-0.86]

0.85 [0.80-0.90]

0.42 [0.40-0.43]

0.41 [0.39-0.44]

0.42 [0.40-0.45]

AIC

-

52001.69

51882.38

BIC

-

52096.91

51977.60

ROC

0.6372

0.6388

0.6359

Variable

Continuous Coverage

1

Not Established with Primary Care
ED High Utilizer

2

3

Inpatient Admission in prior 90 days
Filled 30-Day Anti-HTN Rx from ED

4

Filled Anti-HTN Rx in prior 12 months
Goodness-of-fit tests :
5

Enrolled for 12 months during year of index event
No history of primary care visit in past 12 months, any diagnosis
History of ≥2 prior ED visits in 12 months prior to ED visit, any diagnosis
Filled on day 0 or day 1 after index event
Key: Akaike Information Criterion (AIC); Bayesian Information Criterion (BIC); Area under the Receiver Operating Curve (ROC)

1

2

3

4

5
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Figure 1: Inclusion criteria for combined and cross validation analyses, derived from IBM®
MarketScan® Commercial Database
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Figure 2. Days until first follow-up visit, primary diagnosis HTN
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CONCLUSION
The purpose of this study was to better understand the population who is nonadherent to follow-up after diagnosis of hypertension in the ED, and the findings of this study
have implications for both emergency medicine and primary care. Specifically, several
predictors of non-adherence and associations with adherence were found which can guide
future interventions in the ED and in primary care to increase the quality of referral to
primary care. Future research is needed to understand if the predictors identified in this study
apply to uninsured populations because if prescription of anti-hypertensives increases
adherence to follow-up in both insured and uninsured populations, then current guidelines for
emergency providers should be reconsidered. Additionally, claims data cannot provide
insight on the “why” behind non-adherence to follow-up, and further research is also needed
to better understand barriers to achieving follow-up among the non-elderly, commercially
insured population.
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APPENDICES
Appendix A: Characteristics and adjusted odds ratios of non-adherence, side-by-side
comparison of non-adherence for combined and sensitivity analyses

Combined Analysis

Sensitivity Analysis

Combined Analysis

Sensitivity Analysis

Non-Adherent
(%Row)

Non-Adherent
(%Row)

n= 56,210 (66.2%)

n= 37,292 (43.9%)

Adjusted OR [95%
CI]

Adjusted OR [95%
CI]

47.3; 9.7

46.9: 9.9

46.3; 10.0

0.99 [0.99-1.00]

0.99 [0.99-0.99]

Female

47,970 (56.5%)

31,569 (65.8%)

20,571 (42.9%)

0.99 [0.96-1.02]

0.98 [0.95-1.01]

Full Time Employment

49,244 (58.0%)

31,780 (64.5%)

20,419 (41.5%)

0.89 [0.86-0.92]

0.84 [0.82-0.86]

PPO Insurance

Total (% total)
n= 84,929

Characteristic
Age, mean; standard deviation

54,105 (63.7%)

35,459 (65.5%)

23,167 (42.8%)

0.91 [0.88-0.94]

0.87 [0.85-0.90]

Continuous Coverage
Not Established with Primary
Care

72,347 (85.2%)

47,278 (65.4%)

30,934 (42.8%)

0.94 [0.90-0.98]

0.96 [0.92-1.00]

30,448 (35.9%)

22,829 (75.0%)

18,818 (61.8%)

1.87 [1.81-1.93]

3.07 [2.98-3.17]

ED High Utilizer

9,940 (11.7%)

7,367 (74.1%)

4,761 (47.9%)

1.42 [1.57-1.73]

1.42 [1.36-1.49]

4,134 (4.9%)

2,960 (71.6%)

1,767 (42.7%)

1.36 [1.26-1.46]

1.06 [0.99-1.13]

11,769 (13.9%)

7,278 (61.8%)

5,056 (43.0%)

0.83 [0.80-0.87]

0.92 [0.89-0.96]

64,632 (76.1%)

39,878 (61.7%)

25,430 (39.4%)

0.42 [0.40-0.43]

0.50 [0.48-0.52]

1

2

3

Inpatient Admission in prior 90
days
Filled 30-Day Anti-HTN Rx from
ED
Filled Anti-HTN Rx in prior 12
months
4

Enrolled for 12 months during year of index event
No history of primary care visit in past 12 months, any diagnosis
History of ≥2 prior ED visits in 12 months prior to ED visit, any diagnosis
Filled on day 0 or day 1 after index event
Key: Akaike Information Criterion (AIC); Bayesian Information Criterion (BIC); Area under the Receiver Operating Curve (ROC)

1

2

3

4

5
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Appendix B: Days-supply for prescriptions filled on day 0 or day 1 after ED visit
77.3%

Percent of Individuals

0.8

0.6

0.4

0.2
9.4%
4.0%

2.1%

2.6%

4.6%

0
1-7 Days

14-15 Days

20 Days
30 Days
Days Supply Filled by Individual

90 Days

Appendix C: Regional Distribution of Individuals

Regional Distribution
Unknown
West 2% Northeast
13%
11%

North Central
20%

South
54%

Northeast

North Central

South
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